MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1210/js.2019-00242

Медицинская библиотека · Journal of the Endocrine Society · 2019

Serum Endocannabinoid Levels in Patients With End-Stage Renal Disease.

Moradi Hamid, Park Christina, Igarashi Miki, Streja Elani, Argueta Donovan A, Soohoo Melissa, Daglian Jennifer, You Amy S, Rhee Connie M, Kashyap Moti L, DiPatrizio Nicholas V, Vaziri Nosratola D, Kalantar-Zadeh Kamyar, Piomelli Daniele

СтатьяПеревод в очереди

Аннотация

CONTEXT: Previous studies have shown that the endocannabinoid system plays a major role in energy metabolism through the actions of its main mediators, 2-arachidonoyl-sn-glycerol (2-AG) and anandamide (AEA).

OBJECTIVE

We examined serum levels of major endocannabinoid mediators and their association with clinical parameters in patients with end-stage renal disease (ESRD).

DESIGN AND

SETTING

Serum concentrations of 2-AG and AEA were measured in patients on maintenance hemodialysis (MHD) and controls, and correlations with various clinical and laboratory indices were examined. 2-AG was also measured in age and sex-matched healthy subjects for comparison of levels in patients undergoing MHD.

MAIN OUTCOME MEASURE: Serum 2-AG.

RESULTS

Serum 2-AG levels were significantly elevated in patients with ESRD compared with healthy controls. Higher levels of 2-AG were found in patients on MHD compared to healthy subjects, and similar findings were seen in a second set of subjects in independent analyses. Among 96 patients on MHD, 2-AG levels correlated significantly and positively with serum triglycerides (ρ = 0.43; P < 0.0001), body mass index (ρ = 0.40; P < 0.0001), and body anthropometric measures and negatively with serum high-density lipoprotein cholesterol (ρ = -0.33; P = 0.001) following adjustment for demographic and clinical variables.

CONCLUSIONS

In patients on MHD, levels of serum 2-AG, a major endocannabinoid mediator, were increased. In addition, increasing serum 2-AG levels correlated with increased serum triglycerides and markers of body mass. Future studies will need to evaluate the potential mechanisms responsible for these findings.

Для цитирования: Moradi Hamid, Park Christina, Igarashi Miki, Streja Elani, Argueta Donovan A, Soohoo Melissa, Daglian Jennifer, You Amy S, Rhee Connie M, Kashyap Moti L, DiPatrizio Nicholas V, Vaziri Nosratola D, Kalantar-Zadeh Kamyar, Piomelli Daniele. Serum Endocannabinoid Levels in Patients With End-Stage Renal Disease.. Journal of the Endocrine Society. 2019. DOI: 10.1210/js.2019-00242.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.